Verrica Announces Election of Gary Goldenberg, MD, Verrica’s Chief Medical Officer, to Membership in the American Dermatolo...
March 29 2021 - 7:30AM
Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA), a
dermatology therapeutics company developing medications for skin
diseases requiring medical interventions, today announced that Gary
Goldenberg, M.D., Verrica’s Chief Medical Officer, has been elected
as an active member into the American Dermatological Association
(ADA).
“We congratulate Gary on his well-deserved election into the
ADA, one of the highest honors in dermatology,” said Ted White,
Verrica’s President and Chief Executive Officer. “The ADA is the
oldest and most prestigious dermatological society in the U.S. and
its members are recognized leaders in dermatology research,
education, organizational medicine, and patient care. Gary’s
election into the ADA is a testament to his significant
contributions to dermatology, and we are proud to have Gary on
Verrica’s executive leadership team.”
Founded in 1876, the ADA was the first national dermatological
society in the United States. The ADA’s mission is to recognize,
discuss and develop solutions for problems in the area of
dermatologic health care, research and education. In the execution
of its enduring mission, the ADA has been responsible for the
development of a number of dermatologic organizations including the
American Academy of Dermatology, the Society for Investigative
Dermatology, and the American Board of Dermatology. Membership in
the ADA is achieved through nomination and election based on
meritorious contributions to the field of medicine and
dermatology.
About Verrica Pharmaceuticals Inc.
Verrica is a dermatology therapeutics company developing
medications for skin diseases requiring medical interventions.
Verrica’s late-stage product candidate, VP-102, is in development
to treat molluscum, common warts and external genital warts, three
of the largest unmet needs in medical dermatology. Verrica is also
developing VP-103, its second cantharidin-based product candidate,
for the treatment of plantar warts. The Company has also entered a
worldwide license agreement with Lytix Biopharma AS to develop and
commercialize LTX-315 for dermatologic oncology conditions.
FOR MORE INFORMATION, PLEASE CONTACT:
Investors:A. Brian DavisChief Financial
Officer484.453.3300 ext. 103info@verrica.com
William WindhamSolebury
Trout646.378.2946wwindham@troutgroup.com
Media:Zara LockshinSolebury
Trout646.378.2960zlockshin@troutgroup.com
Verrica Parmaceuticals (NASDAQ:VRCA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Verrica Parmaceuticals (NASDAQ:VRCA)
Historical Stock Chart
From Apr 2023 to Apr 2024